SLP
Get informed when a big investor buys or sells
+ FollowUndervalued by 19% based on the discounted cash flow analysis.
| Market cap | $374.16 Million |
|---|---|
| Enterprise Value | $344.86 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.22 |
| Beta | 1.32 |
| Outstanding Shares | 20,170,000 |
| P/E Ratio | 45.14 |
|---|---|
| PEG | -42.87 |
| Price to Sales | 4.63 |
| Price to Book Ratio | 3.08 |
| Enterprise Value to Revenue | 4.2 |
| Enterprise Value to EBIT | -5.34 |
| Enterprise Value to Net Income | 42 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.11%▼ 79.36% |
|---|---|
| Total Invested | $427,055▼ 99.85% |
| Investors Holding | 6▼ 165.00% |
No data
Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With its subsidiaries, Cognigen, DILIsym Services, and...